Summary of opinion: Tafinlar, 26/03/2026 Positive
Opinion
On 26 March 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Tafinlar. The marketing authorisation holder for this medicinal product is Novartis Europharm Limited.
The CHMP adopted a new indication as follows:
Differentiated thyroid cancer (DTC)
Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refractory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy (for biomarker-based patient selection, see section 4.2).
For information, the full indications for Tafinlar will be as follows:
Melanoma
Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).
Adjuvant treatment of melanoma
Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Non-small cell lung cancer (NSCLC)
Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
Differentiated thyroid cancer (DTC)
Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refractory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy (for biomarker-based patient selection, see section 4.2).
For information, the CHMP also adopted an extension to an existing indication on 26 March 2026 to extend the use of Tafinlar to adolescents from 12 years of age with melanoma. Information on this change is provided in a dedicated summary of opinion available from the EMA website.
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
Notes:
New text in bold
CHMP post-authorisation summary of positive opinion for Tafinlar (VR0000278305)
Adopted
Reference Number:
EMADOC-1700519818-2971643
English (EN) (158.91 KB - PDF)
First published:
27/03/2026
View
Key facts
Name of medicine
Tafinlar
EMA product number
EMEA/H/C/002604
Active substance
dabrafenib mesilate
International non-proprietary name (INN) or common name
dabrafenib
Therapeutic area (MeSH)
Melanoma
Anatomical therapeutical chemical (ATC) code
L01EC02
Marketing authorisation holder
Novartis Europharm Limited
Date of opinion
26/03/2026
Status
Positive
News on Tafinlar
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2026
27/03/2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
27/07/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017
24/02/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015
24/07/2015
More information on Tafinlar
This page was last updated on
27/03/2026
Summary
On 26 March 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Tafinlar. The marketing authorisation holder for this medicinal product is Novartis Europharm Limited. The CHMP adopted a new indication as follows: Differentiated thyroid cancer (DTC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refractory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy (for biomarker-based patient selection, see section 4.2). For information, the full indications for Tafinlar will be as follows: Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. Differentiated thyroid cancer (DTC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refractory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy (for biomarker-based patient selection, see section 4.2). For information, the CHMP also adopted an extension to an existing indication on 26 March 2026 to extend the use of Tafinlar to adolescents from 12 years of age with melanoma. Information on this change is provided in a dedicated summary of opinion available from the EMA website. Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. Notes: New text in bold